151 related articles for article (PubMed ID: 35894811)
21. Surgical treatment of neuroendocrine tumors of the lung.
Daddi N; Ferolla P; Urbani M; Semeraro A; Avenia N; Ribacchi R; Puma F; Daddi G
Eur J Cardiothorac Surg; 2004 Oct; 26(4):813-7. PubMed ID: 15450578
[TBL] [Abstract][Full Text] [Related]
22. Bronchopulmonary neuroendocrine tumors.
Gustafsson BI; Kidd M; Chan A; Malfertheiner MV; Modlin IM
Cancer; 2008 Jul; 113(1):5-21. PubMed ID: 18473355
[TBL] [Abstract][Full Text] [Related]
23. Well-differentiated bronchial neuroendocrine tumors: Clinical management and outcomes in 105 patients.
Pericleous M; Karpathakis A; Toumpanakis C; Lumgair H; Reiner J; Marelli L; Thirlwell C; Caplin ME
Clin Respir J; 2018 Mar; 12(3):904-914. PubMed ID: 28026127
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.
Tabaksblat EM; Langer SW; Knigge U; Grønbæk H; Mortensen J; Petersen RH; Federspiel BH; Ladekarl M
Acta Oncol; 2016; 55(1):3-14. PubMed ID: 26223571
[TBL] [Abstract][Full Text] [Related]
25. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
26. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
Pelosi G; Fabbri A; Cossa M; Sonzogni A; Valeri B; Righi L; Papotti M
Semin Diagn Pathol; 2015 Nov; 32(6):469-79. PubMed ID: 26561395
[TBL] [Abstract][Full Text] [Related]
27. [Pulmonary neuroendocrine neoplasms].
Sayeg Y; Sayeg M; Baum RP; Kulkarni HR; Presselt N; Mäder I; Kunze A; Sänger J; Hörsch D; Bonnet R
Pneumologie; 2014 Jul; 68(7):456-77. PubMed ID: 25006841
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors.
Galván JA; Astudillo A; Vallina A; Crespo G; Folgueras MV; González MV
BMC Cancer; 2014 Nov; 14():855. PubMed ID: 25413006
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and treatment of neuroendocrine lung tumors.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2014 Sep; 50(9):392-6. PubMed ID: 24685201
[TBL] [Abstract][Full Text] [Related]
30. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids.
Pelosi G; Pasini F; Fraggetta F; Pastorino U; Iannucci A; Maisonneuve P; Arrigoni G; De Manzoni G; Bresaola E; Viale G
Lung Cancer; 2003 Nov; 42(2):203-13. PubMed ID: 14568688
[TBL] [Abstract][Full Text] [Related]
31. International trends in pulmonary neuroendocrine cancer studies:a scientometric study.
Tanaka H; Del Giglio A
Einstein (Sao Paulo); 2022; 20():eRW0113. PubMed ID: 36287436
[TBL] [Abstract][Full Text] [Related]
32. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.
Fabbri A; Cossa M; Sonzogni A; Papotti M; Righi L; Gatti G; Maisonneuve P; Valeri B; Pastorino U; Pelosi G
Virchows Arch; 2017 Feb; 470(2):153-164. PubMed ID: 28054150
[TBL] [Abstract][Full Text] [Related]
33. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
Prinzi N; Rossi RE; Proto C; Leuzzi G; Raimondi A; Torchio M; Milione M; Corti F; Colombo E; Prisciandaro M; Cascella T; Spreafico C; Beninato T; Coppa J; Lo Russo G; Di Bartolomeo M; de Braud F; Pusceddu S
Clin Lung Cancer; 2021 May; 22(3):161-169. PubMed ID: 33618994
[TBL] [Abstract][Full Text] [Related]
35. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
[TBL] [Abstract][Full Text] [Related]
36. Value of [
Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
[TBL] [Abstract][Full Text] [Related]
37. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement.
Thomas CF; Tazelaar HD; Jett JR
Chest; 2001 Apr; 119(4):1143-50. PubMed ID: 11296182
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
[TBL] [Abstract][Full Text] [Related]
39. Predictive Indicators of Survival in Patients With Surgically Resected Lung Carcinoid Tumors at a Greek Medical Center.
Georgakopoulou VE; Zygouris E; Nikokiris C; Damaskos C; Pierrakou A; Garmpis N; Garmpi A; Sklapani P; Aravantinou A; Trakas N; Janinis J; Dahabreh J
Cureus; 2020 Sep; 12(9):e10300. PubMed ID: 32923302
[TBL] [Abstract][Full Text] [Related]
40. Lung parenchymal invasion in pulmonary carcinoid tumor: an important histologic feature suggesting the diagnosis of atypical carcinoid and poor prognosis.
Ha SY; Lee JJ; Cho J; Hyeon J; Han J; Kim HK
Lung Cancer; 2013 May; 80(2):146-52. PubMed ID: 23384672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]